



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TAM470

Cat. No.:	HY-148128
CAS No.:	1802498-63-0
Molecular Formula:	C ₄₁ H ₆₇ N ₇ O ₆ S
Molecular Weight:	786.08
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	4°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (127.21 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		1.2721 mL	6.3607 mL	12.7214 mL
		5 mM		0.2544 mL	1.2721 mL	2.5443 mL
10 mM		0.1272 mL	0.6361 mL	1.2721 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<p>1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2 mg/mL (2.54 mM); Clear solution</p> <p>2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2 mg/mL (2.54 mM); Clear solution</p>					

BIOLOGICAL ACTIVITY

Description	TAM470 is a novel cytotoxin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity ^[1] .
--------------------	--

REFERENCES

[1]. Fabre M, et al. OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models. Clin Cancer Res. 2020 Jul 1;26(13):3420-3430.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA